NCT02327169 2020-02-25
A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
Takeda
Phase 1 Completed
Takeda
University of Colorado, Denver
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
Merrimack Pharmaceuticals
Eli Lilly and Company
Boehringer Ingelheim
SWOG Cancer Research Network